HEM파마

376270KOSDAQSector: Pharma & Biotech

₩39,400▲ 0.25%Market cap ₩284.0BAs of Jul 21, 2026 close · updated once daily

Grade F13.5 ptsTop 99% of 2,523 stocks

Financial strength

9.5

Price attractiveness

18.1

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

ⓘ Growth momentum not rated — will be included automatically as data accumulates

Financial strength

9.5

How much debt does it carry relative to equity?

Debt-to-equity ratio

894.0%

✗ Below median · Top 97.8% in sector

Sector median 51.5%

Can it cover what's due within a year?

Current ratio

55.9%

✗ Below median · Top 90.4% in sector

Sector median 191.3%

How much of revenue becomes profit?

Operating margin

-120.1%

✗ Below median · Top 76.3% in sector

Sector median -2.3%

How much did it earn on its own capital?

ROE (return on equity)

-478.1%

✗ Below median · Top 97.4% in sector

Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

Price attractiveness

18.1

Is the price expensive relative to earnings?

P/E (price-to-earnings)

Loss-making (P/E not computable)

✗ Below median · Top 68.1% in sector

Sector median P/E of profitable peers 14.4x · 57% loss-making

Is the price expensive relative to book value?

P/B (price-to-book)

56.82x

✗ Below median · Top 95.7% in sector

Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15